Advertisement

Topics

Medical expert discusses his experience working with Shield Therapeutics' Feraccru drug

03:50 EST 16 Jan 2019 | Proactive Investors

Dr Fraser Cummings,  a consultant gastroenterologist at Southampton General Hospital, spoke to Proactive's Andrew Scott while in London.

''One of the big advantages of Feraccru is that it's extremely well tolerated in the actually quite difficult group of patients who've already failed oral therapies and are quite anxious about taking another iron tablet ... but our data shows that patients do tolerate it well and we hit the targets we're expecting from the drug''.

''With Feraccru we can get patients onto treatment very quickly and patients will then get the benefit of being made iron replete''.

US regulators have confirmed they will make a decision on whether or not to approve Shield Therapeutics PLC’s (LON:STX) Feraccru drug by 27 July 2019.

Original Article: Medical expert discusses his experience working with Shield Therapeutics' Feraccru drug

NEXT ARTICLE

More From BioPortfolio on "Medical expert discusses his experience working with Shield Therapeutics' Feraccru drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...